Fig. 1From: Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose studyStudy design. Number of subjects in each group includes those who received MEDI-551 and those who received placebo. LTFU long-term follow-upBack to article page